North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterin… Read more
North China Pharmaceutical Co Ltd (600812) - Total Liabilities
Latest total liabilities as of September 2025: CN¥14.86 Billion CNY
Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) has total liabilities worth CN¥14.86 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
North China Pharmaceutical Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how North China Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
North China Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of North China Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Italmobiliare S.p.A.
LSE:0RP4
|
UK | €847.43 Million |
|
Clas Ohlson AB ser. B
LSE:0GQE
|
UK | Skr4.37 Billion |
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
China | CN¥383.48 Million |
|
Guangdong Eastone Century Technology Co Ltd
SHE:300310
|
China | CN¥1.23 Billion |
|
Toyobo Co. Ltd
F:TO7
|
Germany | €374.80 Billion |
|
Rumble Inc.
NASDAQ:RUM
|
USA | $64.94 Million |
|
Asana Inc
NYSE:ASAN
|
USA | $652.07 Million |
Liability Composition Analysis (1993–2024)
This chart breaks down North China Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how North China Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for North China Pharmaceutical Co Ltd (1993–2024)
The table below shows the annual total liabilities of North China Pharmaceutical Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥14.80 Billion | +0.75% |
| 2023-12-31 | CN¥14.69 Billion | -2.04% |
| 2022-12-31 | CN¥14.99 Billion | -16.30% |
| 2021-12-31 | CN¥17.91 Billion | +6.14% |
| 2020-12-31 | CN¥16.88 Billion | +30.65% |
| 2019-12-31 | CN¥12.92 Billion | +4.13% |
| 2018-12-31 | CN¥12.40 Billion | +4.50% |
| 2017-12-31 | CN¥11.87 Billion | +6.13% |
| 2016-12-31 | CN¥11.18 Billion | +4.26% |
| 2015-12-31 | CN¥10.73 Billion | +3.97% |
| 2014-12-31 | CN¥10.32 Billion | -0.93% |
| 2013-12-31 | CN¥10.41 Billion | +11.23% |
| 2012-12-31 | CN¥9.36 Billion | -5.93% |
| 2011-12-31 | CN¥9.95 Billion | +25.37% |
| 2010-12-31 | CN¥7.94 Billion | +23.85% |
| 2009-12-31 | CN¥6.41 Billion | +19.43% |
| 2008-12-31 | CN¥5.37 Billion | +2.90% |
| 2007-12-31 | CN¥5.22 Billion | -7.10% |
| 2006-12-31 | CN¥5.61 Billion | +1.22% |
| 2005-12-31 | CN¥5.55 Billion | -5.85% |
| 2004-12-31 | CN¥5.89 Billion | +30.66% |
| 2003-12-31 | CN¥4.51 Billion | +5.08% |
| 2002-12-31 | CN¥4.29 Billion | -7.40% |
| 2001-12-31 | CN¥4.63 Billion | +41.82% |
| 2000-12-31 | CN¥3.27 Billion | +12.65% |
| 1999-12-31 | CN¥2.90 Billion | +44.42% |
| 1998-12-31 | CN¥2.01 Billion | +28.34% |
| 1997-12-31 | CN¥1.56 Billion | +12.93% |
| 1996-12-31 | CN¥1.39 Billion | +34.41% |
| 1995-12-31 | CN¥1.03 Billion | +51.01% |
| 1994-12-31 | CN¥682.69 Million | +63.55% |
| 1993-12-31 | CN¥417.41 Million | -- |